Puerto Rico

Puerto Rico

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.4 (0.34 - 0.46) 2019 Modelled IHME
0.4 (0.34 - 0.46) 2018 Modelled IHME
0.4 (0.33 - 0.46) 2017 Modelled IHME
0.4 (0.34 - 0.46) 2016 Modelled IHME
0.41 (0.34 - 0.47) 2015 Modelled IHME
0.42 (0.35 - 0.48) 2014 Modelled IHME
0.43 (0.36 - 0.49) 2013 Modelled IHME
0.44 (0.37 - 0.49) 2012 Modelled IHME
0.44 (0.37 - 0.51) 2011 Modelled IHME
0.45 (0.38 - 0.52) 2010 Modelled IHME
0.46 (0.38 - 0.53) 2009 Modelled IHME
0.47 (0.39 - 0.53) 2008 Modelled IHME
0.47 (0.39 - 0.54) 2007 Modelled IHME
0.48 (0.40 - 0.55) 2006 Modelled IHME
0.48 (0.40 - 0.56) 2005 Modelled IHME
0.49 (0.41 - 0.56) 2004 Modelled IHME
0.49 (0.41 - 0.57) 2003 Modelled IHME
0.49 (0.42 - 0.57) 2002 Modelled IHME
0.5 (0.42 - 0.57) 2001 Modelled IHME
0.5 (0.42 - 0.58) 2000 Modelled IHME
0.51 (0.43 - 0.59) 1999 Modelled IHME
0.52 (0.44 - 0.60) 1998 Modelled IHME
0.53 (0.45 - 0.61) 1997 Modelled IHME
0.54 (0.45 - 0.62) 1996 Modelled IHME
0.54 (0.45 - 0.63) 1995 Modelled IHME
0.55 (0.45 - 0.64) 1994 Modelled IHME
0.56 (0.46 - 0.65) 1993 Modelled IHME
0.56 (0.46 - 0.65) 1992 Modelled IHME
0.57 (0.46 - 0.66) 1991 Modelled IHME
0.57 (0.46 - 0.68) 1990 Modelled IHME
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.04 (0.03 - 0.05) 2019 Modelled IHME
0.04 (0.03 - 0.05) 2018 Modelled IHME
0.04 (0.02 - 0.05) 2017 Modelled IHME
0.04 (0.02 - 0.05) 2016 Modelled IHME
0.04 (0.03 - 0.05) 2015 Modelled IHME
0.04 (0.03 - 0.05) 2014 Modelled IHME
0.04 (0.03 - 0.05) 2013 Modelled IHME
0.04 (0.03 - 0.05) 2012 Modelled IHME
0.04 (0.03 - 0.05) 2011 Modelled IHME
0.04 (0.03 - 0.05) 2010 Modelled IHME
0.04 (0.03 - 0.06) 2009 Modelled IHME
0.04 (0.03 - 0.06) 2008 Modelled IHME
0.04 (0.03 - 0.06) 2007 Modelled IHME
0.05 (0.03 - 0.06) 2006 Modelled IHME
0.05 (0.03 - 0.07) 2005 Modelled IHME
0.05 (0.03 - 0.07) 2004 Modelled IHME
0.05 (0.04 - 0.07) 2003 Modelled IHME
0.05 (0.04 - 0.07) 2002 Modelled IHME
0.06 (0.04 - 0.08) 2001 Modelled IHME
0.06 (0.04 - 0.08) 2000 Modelled IHME
0.07 (0.05 - 0.08) 1999 Modelled IHME
0.07 (0.05 - 0.09) 1998 Modelled IHME
0.08 (0.05 - 0.10) 1997 Modelled IHME
0.08 (0.06 - 0.11) 1996 Modelled IHME
0.09 (0.06 - 0.12) 1995 Modelled IHME
0.09 (0.07 - 0.13) 1994 Modelled IHME
0.1 (0.07 - 0.13) 1993 Modelled IHME
0.1 (0.07 - 0.14) 1992 Modelled IHME
0.11 (0.08 - 0.15) 1991 Modelled IHME
0.11 (0.08 - 0.15) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
22 (16 - 30) 2019 Modelled IHME
22 (16 - 31) 2018 Modelled IHME
23 (16 - 31) 2017 Modelled IHME
23 (16 - 32) 2016 Modelled IHME
23 (17 - 32) 2015 Modelled IHME
23 (17 - 33) 2014 Modelled IHME
24 (17 - 33) 2013 Modelled IHME
24 (17 - 33) 2012 Modelled IHME
24 (17 - 33) 2011 Modelled IHME
24 (17 - 33) 2010 Modelled IHME
25 (18 - 33) 2009 Modelled IHME
25 (18 - 33) 2008 Modelled IHME
25 (18 - 33) 2007 Modelled IHME
25 (18 - 34) 2006 Modelled IHME
25 (18 - 34) 2005 Modelled IHME
25 (18 - 34) 2004 Modelled IHME
25 (18 - 34) 2003 Modelled IHME
25 (19 - 34) 2002 Modelled IHME
26 (19 - 34) 2001 Modelled IHME
25 (19 - 34) 2000 Modelled IHME
25 (18 - 34) 1999 Modelled IHME
25 (18 - 34) 1998 Modelled IHME
25 (18 - 33) 1997 Modelled IHME
25 (18 - 33) 1996 Modelled IHME
25 (18 - 33) 1995 Modelled IHME
25 (18 - 33) 1994 Modelled IHME
25 (18 - 34) 1993 Modelled IHME
25 (18 - 34) 1992 Modelled IHME
25 (18 - 34) 1991 Modelled IHME
25 (18 - 34) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
15 (10 - 23) 2013 Survey/reported Larney S et al, 2017
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
2.06 (1.68 - 2.51) 2019 Modelled IHME
2.04 (1.68 - 2.51) 2018 Modelled IHME
2.03 (1.66 - 2.50) 2017 Modelled IHME
2 (1.64 - 2.44) 2016 Modelled IHME
1.99 (1.62 - 2.42) 2015 Modelled IHME
1.99 (1.62 - 2.42) 2014 Modelled IHME
1.99 (1.62 - 2.43) 2013 Modelled IHME
1.99 (1.62 - 2.43) 2012 Modelled IHME
1.99 (1.62 - 2.44) 2011 Modelled IHME
1.99 (1.62 - 2.45) 2010 Modelled IHME
1.99 (1.63 - 2.45) 2009 Modelled IHME
2.01 (1.64 - 2.47) 2008 Modelled IHME
2.03 (1.65 - 2.48) 2007 Modelled IHME
2.05 (1.67 - 2.50) 2006 Modelled IHME
2.07 (1.69 - 2.54) 2005 Modelled IHME
2.09 (1.71 - 2.56) 2004 Modelled IHME
2.11 (1.73 - 2.59) 2003 Modelled IHME
2.14 (1.74 - 2.63) 2002 Modelled IHME
2.16 (1.76 - 2.66) 2001 Modelled IHME
2.17 (1.76 - 2.68) 2000 Modelled IHME
2.18 (1.78 - 2.67) 1999 Modelled IHME
2.18 (1.77 - 2.67) 1998 Modelled IHME
2.19 (1.77 - 2.68) 1997 Modelled IHME
2.19 (1.78 - 2.69) 1996 Modelled IHME
2.19 (1.78 - 2.68) 1995 Modelled IHME
2.19 (1.78 - 2.68) 1994 Modelled IHME
2.18 (1.77 - 2.68) 1993 Modelled IHME
2.17 (1.77 - 2.67) 1992 Modelled IHME
2.16 (1.76 - 2.67) 1991 Modelled IHME
2.15 (1.75 - 2.65) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
2.3 (1.30 - 4.20) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
78.4 (73.50 - 82.80) 2015 Survey/reported Abadie R et al, 2016

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
25 (17 - 32) 2019 Modelled IHME
24 (17 - 32) 2018 Modelled IHME
24 (17 - 32) 2017 Modelled IHME
24 (17 - 31) 2016 Modelled IHME
23 (17 - 31) 2015 Modelled IHME
24 (17 - 31) 2014 Modelled IHME
24 (16 - 31) 2013 Modelled IHME
24 (16 - 31) 2012 Modelled IHME
24 (17 - 31) 2011 Modelled IHME
24 (17 - 31) 2010 Modelled IHME
23 (16 - 31) 2009 Modelled IHME
23 (16 - 31) 2008 Modelled IHME
23 (16 - 31) 2007 Modelled IHME
23 (16 - 31) 2006 Modelled IHME
23 (16 - 31) 2005 Modelled IHME
23 (16 - 30) 2004 Modelled IHME
23 (16 - 31) 2003 Modelled IHME
23 (16 - 30) 2002 Modelled IHME
22 (16 - 30) 2001 Modelled IHME
23 (16 - 30) 2000 Modelled IHME
23 (16 - 30) 1999 Modelled IHME
23 (16 - 30) 1998 Modelled IHME
23 (17 - 31) 1997 Modelled IHME
23 (17 - 31) 1996 Modelled IHME
24 (17 - 31) 1995 Modelled IHME
24 (17 - 31) 1994 Modelled IHME
24 (17 - 31) 1993 Modelled IHME
24 (17 - 31) 1992 Modelled IHME
24 (17 - 32) 1991 Modelled IHME
24 (16 - 32) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (10 - 23) 2013 Survey/reported Larney S et al, 2017
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2016
HBV National Action Plan
HBV elimination goal
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.4 (%)
2019
(0.34 - 0.46(%))
IHME
HCV (RNA/cAg+)
2.06 (%)
2019
(1.68 - 2.51(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
108
2019
(73 - 149)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
226
2019
(154 - 317)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.04 (%)
2019, latest modelled
(0.03 - 0.05(%))
IHME

Prevalence PWID

HCV
78.40 (%)
2015, survey/surveillance
(73.50 - 82.80(%))
Abadie R et al, 2016

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
15
2013
(10 - 23)
Larney S et al, 2017
Eligible for HBV generic medicines
Eligible for HCV generic medicines